Detalhe da pesquisa
1.
Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
Cancer
; 122(23): 3608-3614, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27490845
2.
Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Cancer
; 121(16): 2713-9, 2015 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25925789
3.
Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
BJU Int
; 116(3): 358-65, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25124891
4.
External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.
Int J Radiat Oncol Biol Phys
; 115(3): 645-653, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36179990
5.
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
BJU Int
; 109 Suppl 1: 22-9, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22239226
6.
The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy.
Urol Oncol
; 40(1): 6.e21-6.e27, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34315661
7.
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
JAMA Oncol
; 8(3): e216871, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35050303
8.
Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy.
J Urol
; 186(6): 2233-7, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22019035
9.
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.
J Urol
; 186(1): 91-6, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21571341
10.
Long-term outcomes of a prospective randomized trial of 131Cs/125I permanent prostate brachytherapy.
Brachytherapy
; 20(1): 38-43, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33059997
11.
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
JAMA Netw Open
; 4(12): e2138550, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34902034
12.
Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.
JAMA Netw Open
; 4(7): e2115312, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196715
13.
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
Eur Urol
; 80(2): 142-146, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33985797
14.
Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.
BJU Int
; 106(7): 979-85, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20230380
15.
Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease.
Alzheimer Dis Assoc Disord
; 24(1): 85-9, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20556875
16.
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
JAMA
; 302(8): 866-73, 2009 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-19706860
17.
Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.
JAMA Oncol
; 5(2): 213-220, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30452521
18.
Long-term biochemical outcomes using cesium-131 in prostate brachytherapy.
Brachytherapy
; 18(6): 800-805, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427178
19.
Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory Group.
Brachytherapy
; 7(4): 290-6, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18782682
20.
Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOT.
Eur Urol Focus
; 4(1): 64-67, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28753752